Datavault AI has expanded its healthcare-focused blockchain and data monetization licensing agreement with DataMEDS AI, widening the scope of its technology partnership beyond pharmaceutical distribution to include broader healthcare, wellness and patient-centric data applications.
The announcement marks the latest step in the companies' efforts to build an AI and blockchain-enabled healthcare ecosystem focused on managing, securing and monetizing health data. Under the expanded agreement, DataMEDS AI will gain access to Datavault AI's technology across additional healthcare segments, including commercial healthcare, healthspan initiatives, wellness programmes, patient-controlled health records, laboratory information and wearable device data.
The revised licensing arrangement builds on an earlier collaboration announced this year, when Datavault AI and Wellgistics Health outlined plans to combine artificial intelligence, blockchain infrastructure and pharmacy technologies through the creation of DelivMeds AI. Wellgistics Health has since rebranded as DataMEDS AI, reflecting its expanded focus on AI-powered healthcare services.
According to the companies, the broader licence is intended to support healthcare organisations in securely managing medical data while enabling patients to retain greater control over their information. The platform combines Datavault AI's blockchain-based PharmacyChain technology with AI-driven healthcare capabilities, creating infrastructure designed to improve data traceability, security and commercialisation opportunities across the healthcare value chain.
The agreement also reflects the growing convergence of artificial intelligence, blockchain and digital health technologies as healthcare providers seek more secure ways to exchange sensitive medical information while improving operational efficiency. Patient-generated information from wearable devices, diagnostic laboratories and remote monitoring platforms is expected to play an increasingly important role in preventive care and personalised treatment, creating demand for platforms capable of managing large volumes of healthcare data securely.
Datavault AI said the expanded licensing framework is designed to support outcome-based healthcare models by enabling trusted data exchange and facilitating new approaches to healthcare data monetization. The company has increasingly positioned blockchain technology as a foundation for verifying data integrity, enabling digital asset management and supporting secure transactions involving healthcare information.
The companies have also indicated that the broader platform will support healthcare applications extending beyond pharmacy operations, including wellness initiatives, consumer engagement and data-driven health programmes. By integrating AI with blockchain-enabled infrastructure, the partnership aims to improve how healthcare stakeholders collect, analyse and utilise patient information while maintaining transparency and compliance.
The announcement comes as healthcare organisations worldwide accelerate investments in artificial intelligence for clinical decision support, predictive analytics and operational automation. At the same time, blockchain technology is attracting greater attention as a tool for improving data governance, auditability and interoperability across fragmented healthcare systems.
Industry analysts have increasingly identified secure health data infrastructure as a critical enabler of AI adoption, particularly as organisations seek to balance innovation with privacy, regulatory compliance and patient trust.
For Datavault AI, the expanded agreement represents another move to strengthen its presence in healthcare technology by extending the commercial reach of its blockchain and data monetization platform. For DataMEDS AI, the broader licence supports its strategy of building AI-enabled healthcare services that combine pharmacy operations, patient engagement and secure data management into a unified digital ecosystem.